Trial Profile
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Ulixertinib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 26 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.